Patents Assigned to NanoPharmaceuticals LLC
  • Publication number: 20140314665
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 23, 2014
    Applicant: NanoPharmaceuticals LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
  • Publication number: 20140294931
    Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetracâ„¢ or Nanotriacâ„¢) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 2, 2014
    Applicant: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 8802240
    Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: August 12, 2014
    Assignee: Nanopharmaceuticals LLC
    Inventors: Paul J. Davis, Shaker A. Mousa
  • Publication number: 20140199376
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Application
    Filed: February 20, 2014
    Publication date: July 17, 2014
    Applicant: NanoPharmaceuticals LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis